newsfilter
← Latest News
GlobeNewswire·

KALA BIO Reports Third Quarter 2023 Financial Results and Provides Corporate Update

-- Enrollment ongoing in CHASE Phase 2b clinical trial of KPI-012 for PCED; topline data expected in 2H 2024 ---- As of September 30, 2023, $56.1 million in cash and cash equivalents; together with anticipated remaining